RCS - NetScientific PLC - PDS Granted Novel HPV16 Immunotherapy Patent

NetscientificAnnouncement

10/01/2022 14:25

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220110:nRSJ9673Xa&default-theme=true

RNS Number : 9673X  NetScientific PLC  10 January 2022

NetScientific plc

("NetScientific", the "Group" or the "Company")

 

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

London, UK - 10 January 2022 - NetScientific plc (AIM: NSCI), the
international life sciences and sustainability technology investment and
commercialisation Group, announces that its portfolio company, PDS
Biotechnology Corporation (Nasdaq: PDSB), announced that it has been granted
U.S. Patent Application No. 15,724,818 titled "Novel HPV16 Non HLA-Restricted
T-cell Vaccines, Composition and Methods of Use Thereof" by the United States
Patent and Trademark Office (USPTO).

The newly issued patent covers the PDS0101 immunotherapy which consists of a
combination of the Versamune technology platform with a unique mixture of
short protein fragments derived from the cancer-causing virus, HPV16. The
composition promotes the induction of killer (CD8+) T-cells by the immune
system that recognize, and attack cancers caused by infection with HPV16
irrespective of the patients' genetic makeup.

HPV16 is the most oncogenic or cancer-causing type of HPV, and is by far the
most prevalent in patients with advanced HPV-associated cancers, including
anal, cervical, head and neck, penile, vaginal and vulvar cancers. More than
40,500 patients are diagnosed with HPV16-associated cancers each year
according to the International Journal of Cancer. Some of these cancers have
been reported to be increasing in incidence over the last few years.

Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech,
said: "We remain excited about the promising early efficacy and safety data
from our ongoing Phase 2 clinical trials.  The early clinical data coupled
with the recent grant of the PDS0101 patent that runs into late 2037 puts PDS
Biotech in a strong position to progress commercialization of the product to
address a significant unmet need for more effective treatment of advanced
HPV-associated cancers".

Ilian Iliev, CEO of NetScientific, commented: "A strong, effective and
fit-for-purpose patent portfolio is key to effective commercialisation in life
sciences, and a key element in NetScientific's portfolio management and
investment selection strategy. PDS' growing patent portfolio positions the
company well for success, as the company continues to progress its clinical
trials."

The full text of the announcement from PDS Biotechnology is reproduced below
and is available online here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/118-2022-news/584-iotechrantedatentforitsovel16mmunotherap20220110
(https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/118-2022-news/584-iotechrantedatentforitsovel16mmunotherap20220110)

###

 

FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies based on the Company's proprietary
Versamune(®) T-cell activating technology, today announced that it has been
granted U.S. Patent Application No. 15,724,818 titled "Novel HPV16 Non
HLA-Restricted T-cell Vaccines, Composition and Methods of Use Thereof" by the
United States Patent and Trademark Office (USPTO).

 

The newly issued patent covers the PDS0101 immunotherapy which consists of a
combination of the Versamune technology platform with a unique mixture of
short protein fragments derived from the cancer-causing virus, HPV16.  The
composition promotes the induction of killer (CD8+) T-cells by the immune
system that recognize, and attack cancers caused by infection with HPV16
irrespective of the patients' genetic makeup.

 

HPV16 is the most oncogenic or cancer-causing type of HPV, and is by far the
most prevalent in patients with advanced HPV-associated cancers, including
anal, cervical, head and neck, penile, vaginal and vulvar cancers.  More than
40,500 patients are diagnosed with HPV16-associated cancers each year
according to the International Journal of Cancer.  Some of these cancers have
been reported to be increasing in incidence over the last few years.

 

"We remain excited about the promising early efficacy and safety data from our
ongoing Phase 2 clinical trials.  The early clinical data coupled with the
recent grant of the PDS0101 patent that runs into late 2037 puts PDS Biotech
in a strong position to progress commercialization of the product to address a
significant unmet need for more effective treatment of advanced HPV-associated
cancers," stated Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.

 

In partnership with Merck & Co., PDS Biotech is evaluating a combination
of PDS0101 and KEYTRUDA(®) in a Phase 2 study (NCT04260126) in first-line
treatment of recurrent or metastatic head and neck cancer, and also in
second-line treatment of recurrent or metastatic head and neck cancer in
patients who have failed prior checkpoint inhibitor therapy. PDS Biotech is
also conducting a Phase 2 clinical study in both second- and third-line
treatment of multiple advanced HPV-associated cancers with the National Cancer
Institute (NCI). A third Phase 2 clinical trial in first-line treatment of
locally advanced cervical cancer is being performed with The University of
Texas, MD Anderson Cancer Center.

 

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing
pipeline of cancer immunotherapies based on the Company's proprietary
Versamune(®) T-cell activating technology platform. Our Versamune(®)-based
products have demonstrated the potential to overcome the limitations of
current immunotherapy by inducing in vivo, large quantities of high-quality,
highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer
T-cells. PDS Biotech has developed multiple therapies, based on combinations
of Versamune(®) and disease-specific antigens, designed to train the immune
system to better recognize diseased cells and effectively attack and destroy
them.  The Company's pipeline products address various cancers including
HPV16-associated cancers (anal, cervical, head and neck) and breast, colon,
lung, prostate and ovarian cancers.  To learn more, please
visit www.pdsbiotech.com
(https://www.globenewswire.com/Tracker?data=zVbhQx1ohKZmAm5C8DoIyKHW5pJZtNN2hO7xPyyMGXxLjhGsSkHv1NTUnI1eIR3BvpycLVzVw8VK30a1gJ8Bg4hWr2tehMtjLGpsIM-zgao_roUC5df48IlLRORD8fbBMFLRAESiikB9zG_c1OV12qO2VsjmE3Y4RLQgFiD-lZjiXMg6ZkHQu2lVMotZKQd6VgkgngYg5rMKLp51Cmz08LvQ6QYIL2eE-KrNk6usjUcgrG6j_JtPsSHQCvv6lSZb)
 or follow us on Twitter at @PDSBiotech.

 

Forward Looking Statements

This communication contains forward-looking statements (including within the
meaning of Section 21E of the United States Securities Exchange Act of 1934,
as amended, and Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the "Company") and other
matters. These statements may discuss goals, intentions and expectations as to
future plans, trends, events, results of operations or financial condition, or
otherwise, based on current beliefs of the Company's management, as well as
assumptions made by, and information currently available to, management.
Forward-looking statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect," "anticipate,"
"plan," "likely," "believe," "estimate," "project," "intend," "forecast,"
"guidance", "outlook" and other similar expressions among others.
Forward-looking statements are based on current beliefs and assumptions that
are subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those contained in
any forward-looking statement as a result of various factors, including,
without limitation: the Company's ability to protect its intellectual property
rights; the Company's anticipated capital requirements, including the
Company's anticipated cash runway and the Company's current expectations
regarding its plans for future equity financings; the Company's dependence on
additional financing to fund its operations and complete the development and
commercialization of its product candidates, and the risks that raising such
additional capital may restrict the Company's operations or require the
Company to relinquish rights to the Company's technologies or product
candidates; the Company's limited operating history in the Company's current
line of business, which makes it difficult to evaluate the Company's
prospects, the Company's business plan or the likelihood of the Company's
successful implementation of such business plan; the timing for the Company or
its partners to initiate the planned clinical trials for PDS0101, PDS0203 and
other Versamune(® )based products; the future success of such trials; the
successful implementation of the Company's research and development programs
and collaborations, including any collaboration studies concerning PDS0101,
PDS0203 and other Versamune(®) based products and the Company's
interpretation of the results and findings of such programs and collaborations
and whether such results are sufficient to support the future success of the
Company's product candidates; the success, timing and cost of the Company's
ongoing clinical trials and anticipated clinical trials for the Company's
current product candidates, including statements regarding the timing of
initiation, pace of enrollment and completion of the trials (including our
ability to fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected expenses), futility analyses, presentations
at conferences and data reported in an abstract, and receipt of interim
results, which are not necessarily indicative of the final results of the
Company's ongoing clinical trials;  any Company statements about its
understanding of product candidates mechanisms of action and interpretation of
preclinical and early clinical  results from its clinical development
programs and any collaboration studies; the acceptance by the market of the
Company's product candidates, if approved; the timing of and the Company's
ability to obtain and maintain U.S. Food and Drug Administration or other
regulatory authority approval of, or other action with respect to, the
Company's product candidates; and other factors, including legislative,
regulatory, political and economic developments not within the Company's
control, including unforeseen circumstances or other disruptions to normal
business operations arising from or related to COVID-19. The foregoing review
of important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be read in
conjunction with statements that are included herein and elsewhere, including
the risk factors included in the Company's annual and periodic reports filed
with the SEC. The forward-looking statements are made only as of the date of
this press release and, except as required by applicable law, the Company
undertakes no obligation to revise or update any forward-looking statement, or
to make any other forward-looking statements, whether as a result of new
information, future events or otherwise.

 

###

 

For more information, please contact:

 

 NetScientific                                     Via Walbrook PR
 Ilian Iliev, CEO

 WH Ireland (NOMAD, Financial Adviser and Broker)
 Chris Fielding / Darshan Patel                    +44 (0)20 7220 1666

 Walbrook PR                                       +44 (0)20 7933 8780 or netscientific@walbrookpr.com
 Nick Rome / Nicholas Johnson / Paul McManus       07748 325 236 / 07884 664 686 / 07980 541 893

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops,
commercialises and realises shareholder value in life sciences/healthcare,
sustainability and technology companies, which offer significant growth
potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its
portfolio from 8 to 17 companies, either through direct subsidiary, balance
sheet investment or capital under advisory, varying from start-up private
companies to publicly listed equities.

NetScientific delivers shareholder returns through a proactive and hands-on
management approach to their portfolio companies; identifying, investing in,
and helping to build game-changing companies. The Group targets value
inflection points and the release of value through partial or full exits from
trade sales, public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing attractive
expansion prospects.

NSCI can deploy a capital-light investment structure; utilising the power of
the PLC Brand, and the NetScientific balance sheet to anchor future
investments and achieve a multiplier effect by attracting 3rd party investment
for the portfolio companies.

NetScientific is headquartered in London, United Kingdom, and was admitted to
trading on AIM, a market operated by the London Stock Exchange, in 2013
(website: netscientific.net).

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAURASRUUUAAAR